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The risks posed to human health by individual animal 
prion diseases cannot be determined a priori and are difficult 
to address empirically. The fundamental event in prion dis-
ease pathogenesis is thought to be the seeded conversion 
of normal prion protein to its pathologic isoform. We used 
a rapid molecular conversion assay (protein misfolding cy-
clic amplification) to test whether brain homogenates from 
specimens of classical bovine spongiform encephalopathy 
(BSE), atypical BSE (H-type BSE and L-type BSE), classi-
cal scrapie, atypical scrapie, and chronic wasting disease 
can convert normal human prion protein to the abnormal 
disease-associated form. None of the tested prion isolates 
from diseased animals were as efficient as classical BSE 
in converting human prion protein. However, in the case of 
chronic wasting disease, there was no absolute barrier to 
conversion of the human prion protein.
Prion diseases are rare fatal neurodegenerative condi-tions that affect humans and animals. The human dis-
eases include Creutzfeldt-Jakob disease (CJD), Gerstmann-
Sträussler-Scheinker disease, and fatal familial insomnia. 
Most cases of human prion disease are apparently sponta-
neously occurring (sporadic CJD [sCJD]) or are associated 
with mutations in the human prion protein gene, designated 
PRNP (genetic CJD, Gerstmann-Sträussler-Scheinker dis-
ease, or fatal familial insomnia). A small minority of cases 
are acquired by inadvertent human-to-human transmission 
during medical or surgical treatments (iatrogenic CJD).
In contrast, animal prion diseases are generally ac-
quired. This applies to scrapie in sheep, transmissible mink 
encephalopathy, and chronic wasting disease (CWD) in 
deer and elk. No credible evidence exists of a link between 
scrapie and any human prion disease, despite the endemic-
ity of scrapie in many parts of the world and the consequent 
likely human exposure to the scrapie agent, which has been 
attributed partly to a species barrier between sheep and hu-
mans. However, strong epidemiologic, pathologic, and mo-
lecular evidence does indicate that the epidemic of bovine 
spongiform encephalopathy (BSE), primarily in the United 
Kingdom during the 1980s, resulted in a zoonotic form of 
CJD termed variant CJD (vCJD). BSE/vCJD is the only 
known zoonotic prion disease strain.
After identification of BSE and vCJD, active surveil-
lance for animal prion diseases in Europe and elsewhere 
has identified rare atypical prion diseases in sheep and 
cattle. These include Nor98 or atypical scrapie in sheep (1) 
and 2 prion diseases of cattle, bovine amyloidotic spongi-
form encephalopathy or L-type BSE (2) and H-type BSE 
(3), both of which have a pathology and epidemiology dis-
tinct from classical or C-type BSE (4). In addition to these 
new (or newly described) diseases of farmed sheep and 
cattle, CWD in cervids is an acquired, probably contagious 
disease that affects captive and free-ranging deer and elk 
populations primarily in North America (5).
Their distinctive epidemiology, clinical features, neu-
ropathology, PrP biochemistry, and transmission char-
acteristics suggest that scrapie, atypical scrapie, C-type 
BSE, H-type BSE, L-type BSE, and CWD represent dis-
tinct prion strains in their respective species (6,7). Within 
scrapie and CWD, natural strain variation also occurs. The 
prion hypothesis posits that the posttranslational conforma-
tional conversion of a host’s normal cellular prion protein 
(PrPC) by the abnormal form of the prion protein (PrPSc) is 
the fundamental event in prion disease pathogenesis and 
that PrPSc itself constitutes the infectious agent. It follows 
that an aspect of prion host range may be a species barrier 
operating at the molecular level that depends on compat-
ibility between the PrPSc from 1 species and the PrPC from 
another. Similarities in the species-specific primary PRNP 
sequences may account for part of this effect, but prion 
strain and host PRNP polymorphic genotype, both of which 
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probably find expression in the conformation of PrP, affect 
susceptibility in ways not yet fully understood.
A relatively simple empirical approach to assessing 
this molecular barrier is to use cell-free PrP conversion as-
say techniques (8,9) to determine the relative efficiency of 
PrP conversion using natural “seeds” from an infectious 
prion source from the brain of 1 species and a normal brain 
“substrate” from another species. We have previously re-
ported the use of protein misfolding cyclic amplification 
(PMCA) as a model of cross-species prion transmission of 
C-type BSE in cattle and sheep to humans (10). Here we 
report a comparative study of the ability of sheep, cattle, 
and deer prions to convert normal human PrP in this same 
cell-free system.
Methods
Ovine, bovine, and cervine frozen brain tissue from 
prion disease–affected and –unaffected animals were ob-
tained by request from the Animal Health Veterinary Lab-
oratory Agency TSE Archive (AHVLA, Weybridge, UK). 
The cases and brain regions supplied were selected on the 
basis of proven disease status and of brain region with an 
expected high PrPSc load, characteristic of the particular 
prion disease. The prion disease status of the animals in-
volved was determined at AHVLA and/or the Canadian 
Food Inspection Agency’s Ottawa laboratory (Ottawa, 
ON, Canada) by neuropathology and PrP immunohisto-
chemistry. The classical scrapie specimen was of brain 
stem from a field suspect of the animal prion protein gene 
Prnp ARQ/ARQ genotype, and a brain stem specimen 
from an unaffected scrapie suspect of the same genotype 
was also supplied. The atypical scrapie specimen was of 
parietal cortex, also from a field suspect, but of the ARQ/
AHQ genotype, and a corresponding negative control ani-
mal specimen was also supplied. The C-type BSE samples 
were of brain stem from confirmed positive C-type BSE 
suspects obtained through passive surveillance, and the 
corresponding negative control specimen was similarly 
obtained. Both the H- and L-type BSE specimens were of 
frontal cortex from successful experimental bovine trans-
missions conducted at AHVLA. Mid-brain tissue from a 
confirmed CWD-positive and control-negative (unaffect-
ed) elk (both with Prnp codon 132MM genotype) was also 
supplied through the AHVLA.
Frozen half brains from inbred transgenic mouse 
lines expressing human PrPC of the PRNP codon 129 me-
thionine (129MM) and valine (129VV) genotypes (11–13) 
were used for PMCA substrate preparation. The produc-
tion of PMCA substrates from stably transfected human 
293F cells overexpressing human PrPC (exogenous PRNP 
codon 129M and endogenous PRNP codon 129MM) has 
been described (14). A PRNP codon 129 valine expressing 
counterpart was engineered by suppressing expression of 
endogenous PRNP codon 129MM expression with RNAi 
and transient transfection with a PRNP codon 129 valine 
expression vector (designated 129V).
Human brain tissues (frontal cortex) were sampled 
from frozen half brains collected at autopsy with the ap-
propriate consent for tissue retention and research use. The 
vCJD specimen was from a patient (PRNP codon 129MM) 
with definite vCJD as defined by established criteria. The 
non-CJD human brain specimens used for PMCA substrate 
preparation were frontal cortex from patients with Guillain-
Barré syndrome (129MM) and dementia with Lewy bod-
ies (129VV). sCJD specimens from patients with the MM1 
and VV2 subtypes of the disease were used as reference 
standards in certain Western blotting experiments. Ethical 
approval for the use of these tissues in this study is covered 
by Local Research Ethics Committee 2000/4/157.
Brain homogenates were prepared by using a manual 
homogenizer and chilled conversion buffer (150 mM NaCl, 
1% Triton X-100, 1X protease inhibitor cocktail in 1× 
phosphate-buffered saline) to obtain a final 10% wt/vol so-
lution. The homogenized tissue was cleared by centrifuga-
tion at 2,000 rpm for 40 s in a refrigerated centrifuge (4°C), 
and the supernatant was aliquoted and stored at -80°C (15).
We prepared homogenates (10% wt/vol) of C-type 
BSE, scrapie, CWD, L-type BSE, H-type BSE atypical 
scrapie, and vCJD brain. We followed the same method 
used for the substrate brain homogenate.
PMCA experiments were carried out in PCR tubes. Al-
iquots of 10% substrate brain homogenate (or 20% cell ex-
tracts) were mixed with 10% prion disease brain seeds in a 
final volume of 120 μL. Low molecular weight heparin was 
included at 100 μg/mL in all PMCA reactions (15). Before 
sonication, 19 μL of the PMCA reaction mixture (termed 
“frozen” sample) was taken for comparison with the am-
plified sample (termed “sonicated” sample). The reactions 
were incubated into the microplate horn of a programma-
ble sonicator (Misonix 4000, Misonix, Farmingdale, NY, 
USA) at 37°C. A total of 96 PMCA cycles were performed 
comprising 20 s of sonication (at an amplitude of 90%) fol-
lowed by 29 min 40 s of incubation for every cycle (16).
Tissue homogenates and PMCA reaction products 
were digested with proteinase K (50 μg/mL for 1 h at 37°C) 
and detected by Western blotting (10). Detection was with 
3F4 or 6H4 antibodies diluted in 1× phosphate-buffered 
saline, 0.05% Tween 20 (10). The monoclonal antibody 
9A2 was obtained from Central Veterinary Institute Wa-
geningen UR (Lelystad, the Netherlands) (7). Membranes 
were developed by using peroxidase conjugated secondary 
antibody and a luminescent peroxidase substrate ECL-Plus 
(10). Finally, blots were exposed to a photographic film and 
the image acquired using the XRS digital CCD camera sys-
tem (Bio-Rad Laboratories, Hercules, CA, USA). The an-
tibody 6H4 recognizes an epitope in the protease-resistant 
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core of human PrP spanning amino acids 145–153, and it 
cross-reacts with bovine, ovine, and cervine PrP. 3F4 also 
reacts with a sequence in the protease resistant core of the 
human PrP spanning positions 106–112, but 3F4 does not 
recognize PrP from species other than humans and ham-
sters. The combination of protease-digestion and detection 
by 3F4 in these experiments therefore provides a very sen-
sitive method for detecting newly formed human protease-
resistant prion protein (PrPres) (10,17). The antibody 9A2 
reacts with human PrP amino acids 99–101 and cross-re-
acts with ovine, bovine, and cervine PrP.
Results
PrP was confirmed in all animal brain samples in the 
form of 2 major bands in the 20–40-kDa molecular mass 
range, probably corresponding to full-length diglycosylated 
PrP (upper band) and N terminally truncated diglycosylat-
ed or full-length monoglycosylated PrP (lower band). The 
levels of PrP and the electrophoretic pattern were broadly 
similar between prion disease and corresponding negative 
control (unaffected) animal brain samples (Figure 1, panel 
A). However, proteinase K digestion showed differences in 
the amount of PrPres contained in these samples. PrPres was 
most abundant in classical scrapie and CWD samples; lower 
levels were seen in C-, H- and L-type BSE samples and were 
barely detectable at this level of sensitivity in atypical scrapie 
(Figure 1, panel B). Normalizing the Western blot PrPres sig-
nal by adjusting sample loading volumes demonstrated the 
expected PrPres relative mobilities and glycosylation types 
(data not shown). When larger volumes of brain homogenate 
were analyzed, a characteristic <10-kDa band was present in 
the atypical scrapie specimen (Figure 1, panel C).
Figure 1. Determination of total PrP and PrPres level in animal tissues. To characterize the PrP expression levels (total PrP), brain 
homogenates were analyzed by Western blot without digestion with PK. Nineteen microliters of each 10% wt/vol homogenate was loaded 
in each lane (A). To detect the PrPres in the samples, PK digestion (50 μg/mL) was performed to remove PrPC, and the samples were then 
reanalyzed (B). The atypical scrapie and matched normal control animal samples were further analyzed by Western blot both with (+) and 
without (–) prior PK digestion (C) by comparing 3 μL of undigested homogenates with 100 μL of the PK-digested sample concentrated by 
centrifugation. Five microliters of a PK-digested classical scrapie brain homogenate was analyzed in parallel for comparison. The detection 
antibody was 6H4 in (A) and (B) and 9A2 in (C). PrP, prion protein; PrPres, protease-resistant PrP; PK, proteinase K; PrPc, normal cellular 
PrP; M, molecular marker; BSE, bovine spongiform encephalopathy; +, animal prion disease sample; –, matched normal animal control 
sample; CWD, chronic wasting disease; L-BSE, L-type BSE; H-BSE, H-type BSE.
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We evaluated the susceptibility of the human PrP 
(129MM) to in vitro conversion first using the human brain 
homogenate substrate. Western blotting with antibodies 
3F4 and 6H4 both showed readily detectable amplification 
in the samples seeded with C-type BSE and vCJD. (Figure 
2, panel A, lanes 2, 4, and 14, compared with lanes 1, 3, 
and 13). Scrapie, L-type BSE, H-type BSE, and atypical 
scrapie reactions did not show detectable human PrPres for-
mation with the 3F4 antibody (Figure 2, panel A, lanes 6, 
10, 12, and 16). However, 3F4 detected human PrPres in the 
reaction seeded with the CWD brain homogenate (Figure 2, 
panel A, lane 8). Humanized transgenic mouse (129MM) 
brain substrate similarly showed efficient amplification of 
vCJD and C-type BSE and readily detectable amplification 
of CWD PrPres using 3F4 (Figure 2, panel B). Faint bands 
were seen in L-type BSE and H-type BSE PMCA reactions 
when the 6H4 antibody was used. These bands most likely 
represent conversion of endogenous bovine PrPC from the 
inoculum converted to PrPres, rather than conversion of hu-
man PrPC from the substrate (compare lanes 11 and 12 for 
6H4 and 3F4 in Figure 2, panels A, B).
Dilutions of CWD brain homogenate in substrates 
prepared from human brain, transgenic mouse brain, and 
239F cells expressing human PrP (129M or 129V) were 
compared for their ability to support amplification. Ir-
respective of origin, all 3 PRNP 129M-containing sub-
strates supported amplification, albeit with slightly differ-
ent efficiencies (Figure 3, panels A, B, C). All three PRNP 
Figure 2. PMCA of PRNP 
codon 129MM human brain 
homogenate and humanized 
transgenic mice brain 
homogenate seeded with 
C-BSE, scrapie, CWD, L-BSE, 
H-BSE, vCJD, and atypical 
scrapie. PMCA reactions 
using PRNP 129MM human 
brain homogenate (human 
postmortem tissue) (A) and 
PRNP 129MM humanized 
transgenic mouse brain 
homogenate (Tg-Hu) (B) were 
seeded (1:3) with animal prion 
disease brain as indicated. 
Lanes 1, 3, 5, 7, 9, 11, 13, 
and 15 show the samples 
without PMCA. Samples in 
lanes 2, 4, 6, 8, 10, 12, and 
14 were subjected to PMCA. 
Western blotting used the 
antibody 3F4 that enables the 
specific detection of human 
PrP. To compare the PrPres 
levels into the seeds (before 
the PMCA), antibody 6H4 
was also used. PMCA, protein 
misfolding cyclic amplification; 
BSE, bovine spongiform 
encephalopathy; CWD, chronic 
wasting disease; vCJD, variant 
Creutzfeldt-Jakob disease; 
PrP, prion protein; PrPres, 
protease-resistant PrP; M, 
molecular marker.
129V-containing substrates also supported amplification 
(Figure 3, panels D, E, F), although the level of ampli-
fication was lower than for the 129M equivalent. PMCA 
reactions using vCJD brain homogenate as a seed were 
conducted by using these same substrates and are shown 
for comparison (Figure 3, panel G).
Next, we estimated the relative PrPres amount in each 
sample by densitometry and adjusted the volume of 10% 
brain homogenate from the different animal prion dis-
eases used in the PMCA reaction to give roughly equiva-
lent amounts of PrPres seed in each reaction (Figure 4). 
The amount of PrPres in the atypical scrapie specimen 
was so low that a maximum volume of homogenate was 
used. The results of the Western blot analysis of these 
seed PrPres normalized PMCA reactions, using antibody 
3F4, confirmed that amplification efficiency was a func-
tion of seed/substrate compatibility and not simply 
PrPres abundance.
C-type BSE, vCJD, and CWD amplification products 
were normalized and diluted (1:3, 1:6, 1:12, 1:24) in fresh 
human brain tissue homogenate (129MM) and subjected 
to a second round of PMCA. The CWD and C-type BSE 
PMCA reaction products retained their ability to convert 
further human 129M PrP, albeit at a lower efficiency than 
vCJD (Figure 5).
Western blot analysis of PrPres produced by a PMCA 
reaction using human brain homogenate (129MM) seeded 
with CWD brain homogenate (Figure 6, lane 2) showed 
that this PrPres shared the mobility and general glycosyl-
ation profile of type 1 PrPres from sCJD brain (MM1 sub-
type) (Figure 6, lane 1). It was distinct from that of type 
2 PrPres characteristic of sCJD (VV2 subtype) and vCJD 
(Figure 6, lanes 3 and 4, respectively).
Discussion
Multiple factors govern the transmission of prions in 
experimental settings. In addition to infectious dose and 
route, a species or transmission barrier phenomenon is well 
recognized. Within the theoretical confines of the prion 
hypothesis, the most obvious basis of a species barrier ef-
fect would be dissimilarity in PRNP sequence between the 
infectious source and the exposed individual. However, 
PRNP sequence similarity alone does not seem to accurate-
ly predict whether prions are transmissible between spe-
cies, perhaps because interactions between PrPC and PrPSc 
occur as native PrPC and misfolded and aggregated PrPSc 
Figure 3. Susceptibility of human brain, humanized transgenic mice 
brain, and 293F cell extract PrPC to in vitro conversion by CWD brain 
homogenate. PMCA seeded with serial dilutions of CWD brain homogenate 
(1:6, 1:12, and 1:24) were mixed with substrate from 3 different sources: 
human brain homogenate (A, D); transgenic mice that express the human 
PrP (B, E); and 293F human cell extract (C, F). The substrates contained 
human PrP 129M (A–C) or PrP 129V (D–F). These same substrates were 
seeded with vCJD brain homogenate at 1:100 (G). Odd-numbered lanes 
show the samples without PMCA. Even-numbered lanes were subjected 
to PMCA. The PrP detection antibody was 3F4. PrPc, normal cellular prion 
protein; CWD, chronic wasting disease; PMCA, protein misfolding cyclic 
amplification; vCJD variant Creutzfeldt-Jakob disease.
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conformers. The possible effects of species-specific se-
quence difference on PrPC folding are not well understood. 
Neither is the secondary and higher order structure of PrPSc, 
except for clear evidence that different prion strains are as-
sociated with different PrPSc conformers and glycotypes 
(reviewed in 4,18) and that these might exist as a quasispe-
cies or molecular cloud (19). Under such a scenario mo-
lecular compatibility might be difficult to predict.
To isolate and study molecular effects, we have previous-
ly conducted cell-free PrP conversion experiments by PMCA 
using homogenates of bovine and ovine prion disease brain 
samples to seed brain homogenates containing human PrP, as-
sessing the extent of conversion by detection of human PrPres. 
These studies showed that samples of C-type BSE (which is 
a known human pathogen and the cause of vCJD) efficiently 
converted human PrP, with a codon 129 preference similar to 
that of vCJD (MM>MV>VV), whereas samples of classical 
scrapie (which is not thought to be a human pathogen) failed 
to convert human PrP to a measurable extent. Equally impor-
tantly, a sheep BSE isolate resembled C-type BSE and vCJD 
in its ability to convert human PrP, thus underscoring influ-
ence of strain over sequence similarity in determining what 
might be termed a molecular transmission barrier (10).
Here we applied the same approach to a series of ani-
mal prion diseases whose risk to human health is poorly 
characterized. Our results show that under the PMCA con-
ditions used, L-type BSE, H-type BSE, and atypical scra-
pie isolates fail to produce detectable human PrPres. The 
CWD isolate used converted human PrPC, albeit less ef-
ficiently than C-type BSE. This observation remained true 
whether the input animal prion disease brain homogenate 
was normalized by tissue weight or by PrPres abundance 
and whether the PMCA substrate was from human brain, 
PRNP humanized murine brain, or a human-derived and 
human PrPC overexpressing cell line. The conversion of hu-
man PrPC by CWD brain homogenate in PMCA reactions 
was less efficient when the amino acid at position 129 was 
valine rather than methionine. Furthermore, the form of hu-
man PrPres produced in this in vitro assay when seeded with 
CWD, resembles that found in the most common human 
prion disease, namely sCJD of the MM1 subtype.
Previous attempts to determine the transmissibility of 
these prion diseases to humans and thus assess their zoo-
notic potential have used experimental challenge of nonhu-
man primates, humanized PrP transgenic mice, and cell-
free assays with sometimes conflicting results. Successful 
Figure 4. Relative conversion efficiency of human PrP (129M) by different animal prion disease samples. Brain homogenates from animal 
prion diseases were seeded at different volumes adjusted to give roughly equivalent amounts of seeding PrPres and amplified by using PrP 
129M-containing human brain substrate. Human PrPres formation was detected by the 3F4 antibody (A) and seed and newly formed PrPres 
detected using the 6H4 antibody (B). PrP, protein prion; PrPres, protease-resistant PrP; M, molecular marker; BSE, bovine spongiform 
encephalopathy; CWD, chronic wasting disease; L-BSE, L-type BSE; H-BSE, H-type BSE; vCJD variant Creutzfeldt-Jakob disease; M, 
molecular marker.
transmission of CWD and L-BSE to certain nonhuman 
primates has been reported: L-type BSE showing a differ-
ent pathologic profile and a shorter incubation period than 
C-type BSE (20–23). However, Kong et al. (24) reported 
that CWD failed to transmit to humanized PrP 129M over-
expressing mice inoculated with an elk brain homogenate. 
In contrast, Beringue et al. (25) reported that humanized 
PrP 129M overexpressing mice were susceptible to L-type 
BSE and suggested that L-type BSE was more virulent than 
C-type BSE and presented a zoonotic risk. H-type BSE re-
portedly failed to transmit to these same mice. Sandberg et 
al. (26) and Tamgüney et al. (27) confirmed the previous 
report of Kong et al. that CWD fails to transmit to trans-
genic mice, irrespective of whether 1) the mice expressed 
bovine, ovine, or human PrP; 2) the mice expressed the hu-
man 129M or 129V PrP allelic variants; or 3) the CWD 
isolates were from mule deer, elk, or white-tailed deer.
Cell-free approaches to modeling human susceptibil-
ity to animal prion prion diseases also have been published 
(8,10,28–31). Raymond et al. (28) compared the ability of 
CWD, C-type BSE, sheep scrapie, and CJD brain homog-
enates to convert human PrPC metabolically labeled and 
purified from transfected cells. These experiments obtained 
limited conversion of human PrPC by CWD, C-type BSE, 
and scrapie. In contrast to our study, this early cell-free 
system failed to distinguish between scrapie and C-type 
BSE in their ability to convert human PrPC; however, it 
indicated a substantial molecular barrier to conversion of 
human PrPC by CWD PrPSc (28,29), which agrees with this 
report. Kurt et al. (31) reported that PMCA using human 
PrPC overexpressing transgenic mice brain (both 129M 
and 129V lines) as substrate failed to support amplifica-
tion when seeded with CWD cervine brain homogenate. 
Cervidized Prnp transgenic mouse brain homogenate can 
support CWD prion replication (32), and extensive in vitro 
conditioning of a CWD isolate by PMCA in a cervidized 
substrate (or passage in cervidized mice) was sufficient to 
overcome the barrier and enable efficient in vitro ampli-
fication in a humanized transgenic mouse substrate (33). 
Direct comparison of these studies is made difficult by the 
differences in approach (in vivo vs. in vitro), the different 
transgenic constructs used, and the technical details of the 
cell-free conversion assays undertaken (Table). An addi-
tional possibly significant difference between these studies 
is the nature of the CWD isolate used. CWD affects dif-
ferent deer species (some of which show allelic variation 
in their Prnp sequence), but CWD also occurs as different 
biologic strains of agent (34–36). Different strains of CWD 
may have a role in determining transmissibility and con-
version efficiency. Recently, Meyerett et al. (37) reported 
the in vitro strain adaptation of a CWD isolate by serial 
PMCA, similar to that produced by in vivo subpassage.
Figure 5. Properties of C-BSE, CWD, and vCJD amplification 
products in a second round of PMCA. Hu-C-BSE, hu-vCJD, and 
hu-CWD (from a previous round of PMCA) were supplemented 
with fresh human brain homogenate and subjected to a second 
round of PMCA. The reactions were normalized by PrPres level 
and the product diluted (1:3, 1:6, 1:12, 1:24) in fresh human brain 
homogenate (PRNP codon 129MM) before PMCA. Odd numbers 
correspond to samples without PMCA; even numbers correspond to 
the reactions after PMCA (A, B, and C). The PrP detection antibody 
was 3F4. C-BSE, C-type bovine spongiform encephalopathy; CWD, 
chronic wasting disease; vCJD variant Creutzfeldt-Jakob disease; 
PMCA, protein misfolding cyclic amplification; hu, human; PrPres, 
protease-resistant prion protein; M, molecular marker.
Figure 6. PrPres typing of the CWD amplification product. The 
CWD PMCA product derived from amplification in a human brain 
homogenate substrate (PRNP codon 129MM) was compared by 
Western blotting with PrPres from human brain samples from cases 
of sCJD of the MM1 subtype, sCJD of the VV2 subtype, and variant 
CJD. The PrP detection antibody was 3F4. PrPres, protease-resistant 
prion protein; CWD, chronic wasting disease; PMCA, protein 
misfolding cyclic amplification; sCJD sporadic Creutzfeldt-Jakob 
disease; vCJD, variant CJD; hu, human; M, molecular marker.
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The most directly comparable in vivo study to that re-
ported here is Wilson et al. (11), in which a similar series 
of atypical animal prion diseases were used to challenge 
transgenic mice expressing physiologic levels of human 
PrPC. Atypical scrapie; C-, H-, and L-type BSE; and CWD 
all failed to produce disease (or signs of infection) on first 
passage in these mice (11). The use of different animal 
prion disease isolates (and possibly differing species and 
strains of CWD) might explain this discrepancy; however, 
a more fundamental difference might be that the in vivo 
and in vitro model systems assess different aspects of the 
agent and its replication. The in vivo model is undoubtedly 
more complex and arguably more physiologically relevant, 
and the readout is disease; however, it remains disease in a 
mouse, in which the PRNP sequence alone is human. The 
in vitro cell-free model does not assess disease as such, 
only the compatibility of particular combinations of seed 
and substrate homogenates (some of which, in these ex-
amples, were entirely of human origin) to produce PrPres. 
Differences between the in vivo and in vitro models are 
exemplified by the comparison of C-type BSE, and vCJD. 
Both amplify well in PMCA using humanized (129MM) 
brain homogenate as a substrate (10), whereas intracranial 
inoculation of C-type BSE into humanized (129MM) mice 
fails to produce disease (12), unless first experimentally 
transmitted to sheep or goats (13,38,39).
The interpretation of different amplification efficiencies 
as a semiquantitative measure of relative risk is tempting but 
is probably premature and almost certainly an oversimplifi-
cation. The testing of more isolates, especially of CWD in 
deer and elk, is advisable before any firm conclusions can 
be drawn. Additionally, possible strain-specific effects on 
amplification efficiency by the precise PMCA experimen-
tal conditions are difficult to discount and might complicate 
interpretation. The relative amplification efficiencies of C-, 
H-, and L-type BSE might differ intrinsically because cer-
tain strains of sheep scrapie appear to, even when amplified 
in homologous sheep substrates (40). However, we can say 
 
Table. Comparison of the outcomes of experimental transmission and in vitro conversion studies of chronic wasting disease in human, 
humanized, and nonhuman primate model systems* 
Donor animal 
inoculum 
In vivo  In vitro 
Ref 
Species 
inoculated 
Animal (expression 
levels)/codon 129 Transmission  
PrP source (expression 
levels)/codon 129 Method Conversion 
Mule deer, 
white-tailed 
deer, and elk 
  Cells 129M and 129V C-FA Pos (28,29) 
Elk Humanized 
PrP transgenic 
mice 
Tg-40 (1)/129MM Neg   (24) 
Tg-1 (2)/129MM Neg 
Mule deer Squirrel 
monkeys 
Saimiri sciureus (1) Pos   (20) 
Mule deer, 
white-tailed 
deer, and elk 
Humanized 
PrP transgenic 
mice 
Tg(HuPrP)440 (2) Neg   (27) 
Mule deer, 
white-tailed 
deer, and elk 
Squirrel 
monkeys 
Saimiri sciureus (1) Pos   (22) 
Cynomolgus 
macaques 
Macaca fascicularis 
(1) 
Neg 
Mule deer 
and white-
tailed deer 
  Tg-6816 (16)/129M PMCA Neg (31) 
 Tg-7823 (5)/129V PMCA Neg 
Mule deer Humanized 
PrP transgenic 
mice 
Tg-45 (4)/129MM Neg   (26) 
Tg-35 (2)/129M Neg 
Tg-152 (6)/129VV Neg  
White-tailed 
deer 
Humanized 
PrP transgenic 
mice 
HuMM (1)/129MM Neg   (11) 
HuVV (1)/129VV Neg 
Mule deer   Tg-440 (2)/129MM 
 
PMCA Pos 
(after in vitro 
conditioning) 
(33) 
Elk   Human brain 
(1)/129MM 
PMCA Pos This 
article 
Human brain 
(1)/129VV 
PMCA Pos 
 HuMM (1)/129MM 
HuVV(1)/129VV 
293F cell line(4)/129M 
293F cell line(2)/129V 
PMCA 
PMCA 
PMCA 
PMCA 
Pos 
Pos 
Pos 
Pos 
 
*Numbers in parentheses denote the stated expression levels of PrPc into the animal species and cell lines used. PrP, prion protein; C-FA, cell-free assay; 
pos, positive; neg, negative; PrPc, host’s normal cellular PrP. Blank cells indicate no reported data. 
 
 
with confidence that under the conditions used here, none of 
the animal isolates tested were as efficient as C-type BSE 
in converting human PrPC, which is reassuring. Less reas-
suring is the finding that there is no absolute barrier to the 
conversion of human PrPC by CWD prions in a protocol us-
ing a single round of PMCA and an entirely human substrate 
prepared from the target organ of prion diseases, the brain.
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